Cytotoxic T-lymphocyte (CTL) therapy directed to Epstein-Barr virus (EBV) antigens has produced complete tumor responses in patients with EBV associated Hodgkin disease (HD) without toxicity. Many HD tumors, however, are EBV antigen negative. To extend immunotherapy to patients with such EBV negative HD, we propose to target the CD30 molecule, which is expressed by all malignant cells in both EBV positive and EBV negative HD. We hypothesize that we can exploit and extend the demonstrated effectiveness of EBV CTLs by redirecting them to the CD30 molecule, by forcing expression of a chimeric antigen receptor (CAR) targeting this molecule. We also hypothesize that we will be able to further engineer the CAR+ CTLs to overcome the molecular and cellular barriers that protect HD cells from immune attack. These hypotheses will be tested in three specific aims.
In Aim 1, we propose to improve the homing of CAR+ CTLs to HD tumor cells by overexpressing the receptor (CCR4) for the chemokine TARC, which is constitutively produced by HD tumors, and whose receptor is lacking on CTLs.
In Aim 2 we will evaluate whether expansion and persistence of our CCR4+ and CD30CAR+ CTLs is enhanced if these CTLs are further modified to produce their own growth cytokine (IL-15), which is essential to sustain their function. Finally, in Aim 3 we will analyze the interactions between regulatory T cells and our CAR+ CTLs. We will discover whether the modifications we have made allow the CAR+ CTLs to resist the inhibitory effects of the regulatory T cells that dominate sites of HD tumor, or whether alternative strategies will be required. The modifications we propose will be tested pre-clinically in vitro and in vivo and will form the basis of our continued clinical investigation of T- cell therapy for cancer.
We have had success in treating patients with relapsed Hodgkin disease (HD) by using their own immune cells directed to viral proteins that are often on the tumor cells. We now want to extend the application of this promising treatment by targeting other proteins that are on all HD cells, and by making the immune cells more potent.
|Arber, Caroline; Feng, Xiang; Abhyankar, Harshal et al. (2015) Survivin-specific T cell receptor targets tumor but not T cells. J Clin Invest 125:157-68|
|Perna, Serena K; Pagliara, Daria; Mahendravada, Aruna et al. (2014) Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 20:131-9|
|Chakraborty, Rikhia; Mahendravada, Aruna; Perna, Serena K et al. (2013) Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica 98:533-7|
|Perna, Serena K; De Angelis, Biagio; Pagliara, Daria et al. (2013) Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 19:106-17|
|Savoldo, Barbara; Dotti, Gianpietro (2013) Chimeric antigen receptors (CARs) from bench-to-bedside. Immunol Lett 155:40-2|
|Arber, C; Abhyankar, H; Heslop, H E et al. (2013) The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther 20:958-62|
|Huye, Leslie; Savoldo, Barbara (2012) Cancer battlefield: six characters in search of an author. Immunotherapy 4:753-5|
|Chakraborty, Rikhia; Rooney, Cliona; Dotti, Gianpietro et al. (2012) Changes in chemokine receptor expression of regulatory T cells after ex vivo culture. J Immunother 35:329-36|
|Hoyos, V; Savoldo, B; Quintarelli, C et al. (2010) Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24:1160-70|
|Micklethwaite, Kenneth P; Savoldo, Barbara; Hanley, Patrick J et al. (2010) Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 115:2695-703|
Showing the most recent 10 out of 15 publications